Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion session - Translational research 2

1375 - High tumor mutational burden (TMB) and PD-L1 have similar predictive utility in 2L+ NSCLC patients (pts) treated with anti-PD-L1 and anti-CTLA-4


21 Oct 2018


Poster Discussion session - Translational research 2


Targeted Therapy;  Immunotherapy

Tumour Site


Brandon Higgs


Annals of Oncology (2018) 29 (suppl_8): viii14-viii57. 10.1093/annonc/mdy269


B.W. Higgs

Author affiliations

  • Translational Medicine, MedImmune, 20878 - Gaithersburg/US


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1375


PD-L1 can predict benefit from anti-PD-1/L1 therapies; TMB is an emerging biomarker that may have additional predictive utility. We compared the utility of high TMB and PD-L1 to predict outcomes in NSCLC non-squamous pts treated with anti-PD-L1 (durvalumab) and anti-CTLA-4 monoclonal antibodies (tremelimumab, D+T).


NCT02000947 was a ph 1b study in advanced NSCLC; this exploratory study focused on a cohort of IO-naive non-squamous NSCLC who progressed after 1 prior platinum-based therapy. Pts were treated with D 20 mg/kg Q4W up to 12 months and T 1 mg/kg Q4W with the first 4 cycles of D. By 20 OCT 2017, 214 pts received D+T. DNA sequencing was conducted with the FoundationOne CDxTM on 106 tumors and IHC was performed on tumoral PD-L1 on 193 biopsies using the validated SP263 Ventana assay, all of sufficient quality. NSCLC with ≥25% tumor cells stained for PD-L1 at any intensity were PD-L1+ and high TMB was the top tertile of nonsynonymous mutations per Mb (11.41). KM, Cox PH models and Spearman’s rho were calculated; RECIST v1.1 was used for response.


Of 200 biopsies evaluated for TMB, 106 (53%) provided usable data. PD-L1 was modestly correlated with TMB (r = 0.3, p = 0.002). PD-L1+ pts had higher ORR, PFS and OS compared to PD-L1-. TMB high pts had higher PFS than TMB low. HRs for PD-L1+ and TMB high were similar. TMB high/PD-L1+ pts did not have substantially better ORR than single positive pts, and TMB low/PD-L1- had the lowest response.Table: 65PD

# Pts (# events [PFS])ORR % (95% CI)Median PFS, mo (95% CI)PFS HR (95% CI); p
TMB high37 (27)29.7%7.1 (1.7,9.1)0.60 (0.38,0.96); 0.032
TMB low69 (59)10.1%1.7 (1.6,3.6)
PD-L1+57 (39)35.1%7.1 (3.5,9.2)0.55 (0.38,0.80); 0.0018
PD-L1-136 (114)11.8%3.3 (1.7,3.6)


The predictive utility of TMB was similar to that of PD-L1 in this cohort of NSCLC pts treated with D+T. This abstract was withdrawn from ASCO.

Clinical trial identification


Legal entity responsible for the study

Medimmune LLC.


Medimmune LLC.

Editorial Acknowledgement


B.W. Higgs, C.A. Morehouse, P.Z. Brohawn, S. Sridhar, R. Raja, G. Gao, J. Englert, K. Ranade: Employment: Medimmune/AstraZeneca; Stock ownership: AstraZeneca.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.